Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01336608 · ClinicalTrials.gov registry record · Phase 3
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 446
- Enrollment target
NCT01336608 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 446 participants.
The verdict
NCT01336608, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 446 participants
- Enrollment target
Study Summary
The purpose of the study is to investigate the effect of fluticasone furoate/vilanterol Inhalation Powder on arterial stiffness compared with placebo and vilanterol over a 24-week treatment period in subjects with COPD and aortic pulse wave velocity of 11.0 m/s or above.
Interventions
- DRUG Placebo
- DRUG Fluticasone Furoate/Vilanterol
- DRUG Vilanterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 446 participants |
| Start Date | 2011-03-04 |
| Est. Completion | 2014-11-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01336608
The ClinicalTrials.gov registry entry for NCT01336608 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 446 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01336608 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01336608 about?
NCT01336608 is a clinical study titled "A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD". The purpose of the study is to investigate the effect of fluticasone furoate/vilanterol Inhalation Powder on arterial stiffness compared with placebo and vilanterol over a 24-week treatment period in subjects with COPD and aortic pulse wave velocity of 11.0 m/s or above.
What is the current status of trial NCT01336608?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 446 participants. The study started on 2011-03-04. Estimated completion is 2014-11-04.
What interventions are being tested in trial NCT01336608?
The interventions under investigation include: Placebo (DRUG), Fluticasone Furoate/Vilanterol (DRUG), Vilanterol (DRUG).
Who is sponsoring clinical trial NCT01336608?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.